Viromed Medical AG: Strategic healthcare investor acquires further shares in private placement

Viromed Medical AG: Strategic healthcare investor acquires further shares in private placement

Pinneberg, 7 March 2025 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has been informed by its majority shareholder (together with his wife) and CEO Uwe Perbandt about a further off-market placement of a total of 900,000 shares from his holdings. As part of a further private placement, shares with a volume of around 4.44% of the Company’s share capital were thus reallocated to a strategic healthcare investor, who had previously acquired 1,250,000 shares in Viromed Mediacal AG, corresponding to 6.17% of the share capital, as announced on 5 February 2025, as part of a reallocation. As a result, the strategic healthcare investor now holds 10.62% of the shares in Viromed Medical AG. Uwe Perbandt and his wife remain the majority shareholders of the Company and will continue to fully support the further development of Viromed Medical AG.

Uwe Perbandt, CEO of Viromed Medical AG, explained: “The additional relocation of a portion of my shares underlines the growing commitment of our strategic investor in the healthcare industry, who recognizes the recent progress as corresponding milestones. This placement will further strengthen the future of Viromed and is in the best interest of all shareholders and the Company.”

About Viromed Medical AG:

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG is pursuing the goal of further advancing the use of CAP in medicine in the coming years and realizing the corresponding growth potential.

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
E-Mail: kontakt@viromed-medical.de
www.viromed-medical-ag.de